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Abstract Induced pluripotent stem cells and embryonic
stem cells have revolutionized cellular neuroscience, pro-
viding the opportunity to model neurological diseases and
test potential therapeutics in a pre-clinical setting. The
power of these models has been widely discussed, but the
potential pitfalls of stem cell differentiation in this research
are less well described. We have analyzed the literature
that describes differentiation of human pluripotent stem
cells into three neural cell types that are commonly used to
study diseases, including forebrain cholinergic neurons for
Alzheimer’s disease, midbrain dopaminergic neurons for
Parkinson’s disease and cortical astrocytes for neurode-
generative and psychiatric disorders. Published protocols
for differentiation vary widely in the reported efficiency of
target cell generation. Additionally, characterization of the
cells by expression profile and functionality differs
between studies and is often insufficient, leading to highly
variable protocol outcomes. We have synthesized this
information into a simple methodology that can be fol-
lowed when performing or assessing differentiation
techniques. Finally we propose three considerations for
future research, including the use of physiological O2
conditions, three-dimensional co-culture systems and
microfluidics to control feeding cycles and growth factor
gradients. Following these guidelines will help researchers
to ensure that robust and meaningful data is generated,
enabling the full potential of stem cell differentiation for
disease modeling and regenerative medicine.
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Introduction
Studying mechanisms and potential therapeutic targets of
neurodegenerative diseases has historically been limited by
the timely access to the affected tissue. Furthermore, the
use of animal models for disorders without a clear genetic
cause has shown to be of limited translational value to the
clinical setting. The possibility of creating neuronal cul-
tures from human stem cells, particularly from induced
pluripotent stem cells (iPSC) of diagnosed individuals, has
received wide attention for the potential of creating trans-
latable disease-in-a-dish models [1]. Following the
discovery of iPSCs, several high profile publications have
fuelled the enthusiasm for their use in research into
Parkinson’s disease [2], Alzheimer’s disease [3, 4], motor
neurone disease [5] and mental disorders [6].
While optimized methods for reprogramming iPSCs
have broadly been adopted (recently reviewed by Revilla
et al. [7]), the protocols for differentiating iPSCs into
neuronal cultures vary significantly for the same desired
cell types. Strategies for converting stem cells into termi-
nally differentiated cells predominantly follow
observations from developmental mouse and rat studies,
intending to model the in vivo progression of chemical
signaling. However, variations in composition, concentra-
tion and timing of the signaling molecules can lead to
marked differences in the resulting cultures and maturation
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stage of the desired cells. Furthermore, recent studies
report variations in the differentiation efficiency between
different stem cell lines, which is particularly relevant if
the differences are diagnosis-specific [8, 9]. Finally, novel
culturing methods, including three-dimensional cultures
and hypoxic conditions, have been reported to influence the
differentiation efficiency [10, 11]. To ensure the generation
of meaningful results, stem cell derived cultures will
therefore need to undergo thorough characterization to
identify the composition and functionality of the differen-
tiated cells.
The development and maturation of neuronal cells
depends on different types of chemical signaling in vivo.
Initially, growth factors and chemoattractants released into
the extracellular space by progenitor cells trigger location
specific differentiation [12]. Upon neurite formation, local
neurotransmitter release guides dendrite development and
cell maturation to form the dynamic networks of the central
nervous system [13, 14]. While growth factor signals can
be recreated in vitro through time-dependent media sup-
plementation, location and cell type-specific synaptic
inputs cannot easily be modeled. It is therefore highly
relevant to consider the developmental and maturation
environment of the desired cell type when deciding to
study disease processes in iPSC derived cultures.
With the present review, we provide an overview of
existing differentiation strategies for neurodegenerative
disease-relevant cell types of forebrain cholinergic neu-
rons, midbrain dopaminergic neurons and cortical
astrocytes. Advances in motor neuron differentiation have
been extensively reviewed, including recently [15]. We
address the variation in protocol efficiencies by providing a
checklist that can be used to evaluate the quality and
reproducibility of in vitro differentiation. Finally, we dis-
cuss recent culturing method developments aiming to
improve the quality of stem cell derived neural cultures.
Human stem cell derived in vitro disease models have
the potential to overcome the limitations of existing cell
line work and can become a vital research stream next to
animal modeling strategies. However, to progress in dis-
ease understanding and treatment development, the quality
and biological relevance of stem cell-derived cultures need
to be ensured.
From in vivo development to in vitro
differentiation
Forebrain cholinergic neurons
Cholinergic neurons in the mammalian brain, including
basal forebrain cholinergic neurons (BFCNs) and
interneurons of the striatum, are defined by the production
of acetylcholine (ACh) and its use as a neurotransmitter.
BFCNs play an important role in cognitive functions, such
as learning, memory and attention, and are implicated in
the rapid eye movement sleep phase. The loss of BFCNs in
neurodegenerative disorders, including Alzheimer’s dis-
ease, thus leads to severe cognitive impairments and
memory deficits [16, 17].
Mammalian development of cholinergic neurons
During mammalian development, cholinergic neurons are
derived from neural precursors of the ectoderm layer. After
the formation of the neural tube, a selection of cells start to
respond to high concentrations of sonic hedgehog (SHH), a
morphogen that induces ventralization (differentiation
towards the anterior) of the neural tube, and low concen-
trations of Wnt, a morphogen that induces caudalization
(differentiation towards the posterior) [18]. The mor-
phogens retinoic acid (RA), bone morphogenetic proteins
(BMPs) and fibroblast growth factors (FGFs) are also
known to play a key role in telencephalon development, the
most anterior region of the developing brain [19]. In
rodents and primates, BFCNs are formed in the medial
ganglionic eminence (MGE), a ventral region of the
telencephalon, with projections to the hippocampus and
frontal cerebral cortex [20], areas implicated in the cog-
nitive and psychological deficits of neurodegenerative
diseases [21, 22].
The anterior/posterior patterning of the brain begins at
embryonic day 8.5 (E8.5) in mice, when the telencephalic
neuroepithelia expresses the transcription factors forkhead
box G1 (FOXG1) and paired box 6 (PAX6) [23–25]. SHH
together with FOXG1 induce the expression of FGFs,
which activate downstream transcription factors charac-
teristic of the ventral patterning. The expression of NK2
homeobox 1 (NKX2.1) at E9.5 defines the MGE region and
by day E12.5 the expression of LIM homeobox 8 (LHX8)
and insulin gene enhancer protein 1 (ISL1) determine a
cholinergic fate. Choline acetyl transferase (ChAT)
expression in neural precursor cells arises at postnatal day
7 (P7), with ChAT-positive cells increasing in number after
P8 and remaining stable during adulthood [26].
While the full range of molecular drivers for BFCN
development remains to be mapped, several essential fac-
tors for the differentiation, growth and survival of BFCNs
have been identified. The cholinergic phenotype of
embryonic BFCNs is induced and maintained by BMP9
[27], whilst FGF2 and brain-derived neurotrophic factor
(BDNF) stimulate cholinergic differentiation [28, 29]. The
maturation, neurotransmitter phenotype, arborisation and
survival processes are finally controlled through nerve
growth factor (NGF) signaling [30]. These growth factors
drive the gene expression profile of BFCNs through
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specific transcription factors, such as LHX8 [31] and
GBX1, a gastrulation box homeodomain protein, which can
be used in the differentiation of BFCNs in vitro [32].
Characteristics of mature cholinergic neurons
Basal forebrain cholinergic neurons are characterized by
their neuroanatomical location and the expression of ACh
related genes. The key markers used to identify mature
cholinergic neurons are involved in ACh synthesis (choline
acetyltransferase, ChAT), transport (e.g., the vesicular ACh
transporter, vAChT and the choline transporter, Cht1) and
hydrolysis (e.g., acetylcholinesterase). Since NGF levels
are directly related to the health and function of BFCNs
[30], the high affinity neurotrophin receptor, TrkA, and the
low affinity receptor, p75NTR, are also useful identifiers.
Due to their extraordinary complexity, the characteri-
zation of the complete morphology of cholinergic neurons
has been difficult. In vitro studies from primary cultures
showed that BFCNs have large cell bodies with two to four
primary neurites [33]. However, a recent study in mice has
demonstrated that individual cholinergic neurons from the
basal forebrain region have axons that develop up to 50 cm
in length, with approximately 1000 branches [34]. The
electrophysiological profile of BFCNs has been character-
ized in rats, where BFCNs show regular spontaneous
discharge patterns with mean spontaneous activity of 20
impulses/s [35]. Further key characteristics of the BFCNs
are a slow spiking activity (4–10 Hz) and slow after
potentials (400–700 ms) when compared with non-cholin-
ergic neurons (3–60 ms) [36], which have also been shown
in iPSC-derived BFCNs [37]. The addition of NGF can
increase slow depolarization and enhance synaptic activity
by upregulating ChAT activity [38].
Current differentiation strategies for cholinergic neurons
Cholinergic neurons derived from human embryonic stem
cells (ESCs) and iPSCs can become an important tool for
modeling neurodegenerative diseases, such as Alzheimer’s
disease. However, due to their complexity, few studies
have successfully differentiated BFCNs. Most of these
studies start the differentiation process with the generation
of embryoid bodies, followed by the formation of neural
rosettes and neurospheres. These neurospheres contain
neural precursor cells (NPCs) from which the different
protocols will generate the BFCNs (Fig. 1).
Nilbratt et al. assessed growth factors that could induce
forebrain identity [39]. BDNF, NGF, ciliary neurotrophic
factor (CNTF) and neurotrophin 3 (NT-3) were tested as
candidates, but only BDNF and NGF reliably induced the
expression of both NKX2.1 and LHX8 [39]. Following
this, Bissonnette et al. [32] published a comparison of two
different protocols to generate functional BFCNs from
hESC. In both cases cells were pre-treated with RA, SHH
and FGF8 [32]. One option relied on diffusible ligands for
differentiation (Table 1), while the other additionally
transfected an expression plasmid encoding the transcrip-
tion factors LHX8 and GBX1 and a fluorescent tag.
Transfected cells could be purified by fluorescence acti-
vated cell sorting, a step that increased the ratio of BFCNs
in the final culture to 94 %. This method has also allowed
the successful differentiation of BFCNs derived from
iPSCs, as described by the same group, showing that the
iPSC-derived BFCNs can be used as a model for Alzhei-
mer’s disease, producing disease-related pathological
features [40].
Using a different strategy, Crompton et al. published a
protocol for non-adherent differentiation of iPSCs into
BFCNs [37]. In this procedure, neurospheres were treated
with Nodal/transforming growth factor beta (TGF-b)
inhibitor (small molecule inhibitor, SMI) to induce the
endogenous expression of SHH, instead of its direct addi-
tion, resulting in a 90 % efficiency of b-III-tubulin/ChAT-
expressing cells after 90 days [37].
Overall, only two of the mentioned protocols success-
fully reached [90 % ChAT-expressing cells. The main
differences between the protocols are in their way of cul-
turing (i.e., adherent by Bissonnette et al. [32] versus non-
adherent by Crompton et al. [37]). This highlights the need
for independent replication of both protocols to provide
evidence for the use of either strategy. One potential
advantage of the protocol developed by Bissonnette et al.
involves using plasmid transfection via electroporation to
trigger BFCN differentiation [32]. While this step allows
fluorescently tagged cell sorting for purified cultures,
transfection efficiency likely differs between each stem cell
line and thus requires thorough optimization and counting
of viable cells after sorting to produce replicable cultures.
In summary, the majority of published protocols for
cholinergic differentiation are based on the initial addition
of SHH or its endogenous induction to induce ventral
forebrain fate and the expression of developmental markers
of the MGE. While treatment with NGF has been shown to
be highly important for the generation of mature ChAT-
expressing BFCNs (Fig. 1; Table 1), the incomplete func-
tional characterization of mature BFCNs limits us from
recommending a particular protocol. This shortcoming can
be addressed by transplanting BFCN precursors into
rodents to compare the in vitro maturation with in vivo
maturation of cells from the same origin. While three of the
listed protocols show that engrafted BFCN precursors
develop into integrated BFCNs [32, 37, 41], none of the
studies compared the in vitro differentiated cells with their
in vivo counterparts. We can, thus, not yet recommend a
reliable BFCN differentiation protocol.
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Midbrain dopaminergic neurons
Midbrain dopaminergic (mDA) neurons are predominantly
expressed in the substantia nigra pars compacta (SNc) and
the ventral tegmental area (VTA) in rodents and primates
[42–44]. SNc mDA neurons are required for initiation and
control of motor functions, while VTA mDA neurons are
important for reward behavior and cognition. Both nuclei
are implicated in severe disorders, with degeneration of
SNc mDA neurons being a hallmark of Parkinson’s dis-
ease, and impaired signaling of VTA mDA neurons being
implicated in psychiatric disorders, such as schizophrenia
and bipolar disorder. There is thus strong interest in dif-
ferentiating human mDA neurons in vitro to study
mechanisms contributing to the onset and progression of
these disorders.
Mammalian development of mDA neurons
Midbrain DA neurons arise from NPCs of the ventral
mesencephalon in mammals. The expression of aldehyde
dehydrogenase 1 by progenitor cells at embryonic day 9.5
Fig. 1 Schematic diagram of basal forebrain cholinergic neuron
differentiation. The differentiation of basal forebrain cholinergic
neurons from pluripotent stem cell colonies is driven by transitions
between two- and three-dimensional culturing stages, as well as timed
exposure to essential growth factors, such as NGF. The presence or
absence of developmental and maturation markers are essential
guides to monitor the differentiation progress at each culturing stage
towards mature, functional forebrain cholinergic neurons
Table 1 Comparison of basal forebrain cholinergic neuron differentiation protocols
Differentiation
protocol




Duan et al. [40]
Liu et al. [41] Crompton et al. [37]
Duration (days) ND 34 34 45 90
Efficiency
(ChAT? cells)
69–78 % 85 % 65 %; 94 % after
FACS purification
38 % [90 %
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(E9.5) in mice triggers the development of post-mitotic
cells, which produce the dopamine synthesizing enzyme
tyrosine hydroxylase (TH) [45]. These mDA neuron pre-
cursors express nuclear receptor related 1 protein (NURR1)
at E10.5 and differentiate into dopamine producing, TH-
expressing neurons at E11.5 in the mediobasal floor plate
[45, 46]. Neurogenesis of mDA neurons peaks at E12.5 in
mice and E80 in non-human primates [42, 47–49], with
mDA neuronal development occurring earlier in the SNc
than VTA [47]. While the timing of prenatal mDA neu-
rogenesis is similar in mice and rats, neurite development
and migration is completed in postnatal week one in mice
and three in rats [46, 50]. This suggests a likely further
extension to the developmental period in primates that has
yet to be mapped in humans.
Neurogenesis of mDA neurons is driven by intrinsic and
extrinsic signaling factors with precise temporal release
patterns. The specific events have recently been reviewed
in detail [51, 52]. Briefly, mDA progenitor cells receive
target-derived neurotrophic factors from the mesen-
cephalon floor plate of the dorsoventral neural tube axis
(SHH and FGF8) [53–55] and later from the striatum (glial
cell-derived neurotrophic factor, GDNF and neurturin,
NRTN) [56–58]. Additional factors, such as BDNF,
TGF3b, RA and ligands for members of the frizzled family
of seven transmembrane receptors (Wnt1 and Wnt5a),
promote mDA neuronal development and midbrain orga-
nization [59–63]. The variations in developmental timing
of mDA neurons between species suggest an importance
for the scheduling of the different factors between stem
cells of different organisms.
Characteristics of mature mDA neurons
Midbrain DA neurons develop into a distinct cell type
throughout their differentiation and maturation process
which can be identified through functional, morphological
and protein expression characteristics. The functional
profile of mDA neurons requires the production of several
key proteins, which have therefore been used as markers to
identify mDA neurons within brain regions and in mixed
primary cultures. The dopaminergic profile ultimately
relies on the synthesis of dopamine from L-3,4-dihydrox-
yphenylalanine (L-DOPA) by TH, the re-uptake of
dopamine from the synaptic cleft by dopamine transporters
(DAT1), as well as the auto feedback loop, regulating
dopamine production through activation of presynaptic
dopamine receptor 2 (DR2).
Promoter-driven expression or antibody labeling of TH
has consequently been used to identify DA neurons in post
mortem tissue [64], primary cell cultures [65] and human
stem cell derived differentiated neurons [66]. However, TH
is required for the first synthesis step of catecholamines and
therefore also present in noradrenergic cells [67]. In addi-
tion, TH expression is tightly regulated by neuronal activity
via modulation of histone acetylation levels and is neither
specific to DA neurons nor expressed at consistent levels in
these cells [68]. Selection based on DAT expression has
shown high specificity for mature mDA neurons from the
VTA, with lower expression levels in the SNc [69]. Con-
sequently, purifying embryonic mouse brain cultures for
DAT resulted in a higher proportion of mature mDA
neurons than selecting for TH [70, 71]. To address limi-
tations of TH and DAT expression based selection, a recent
study explored cell surface proteins with high specificity
for mDA neurons. Ganat et al. identified the nicotinic ACh
receptor subunit 3 and 6 to be highly colocalized with
mDA neurons in the mouse [72], suggesting that these
receptor subunits could be additional selection options for
stem cell-derived mDA neurons [73], following confirma-
tion in human samples.
The morphological profile of mDA neurons in vivo is
dominated by their long projections, connecting the VTA
with the neocortex via the mesocortical pathway and the
SNc with the striatum via the nigrostriatal pathway. Lim-
itations of the in vitro environment restrict this structural
characteristic, moving the focus onto cell body size and
shape. Midbrain DA neurons in the VTA are reportedly
smaller and rounder than their elongated SNc relatives (13
vs. 19 lm Ø) [74]. Additionally, VTA mDA neurons are
predominantly multipolar with radial projections while
SNc mDA neurons have largely lateral and ventral pro-
jecting dendrites [75]. Although the reported characteristics
are based on rodent in vitro and in vivo studies, they are
expected to be observed in stem cell derived mDA neurons
[76].
The electrophysiological profile of mDA neurons has
been characterized in vivo and in vitro, identifying specific
action potential patterns. Midbrain DA neurons can express
either high bursts ([15 Hz) or slow background (1–5 Hz)
action potential discharges [64], with each discharge
starting with a prominent hyperpolarizing pulse [77] and
depend on the G-protein-regulated inward-rectifier potas-
sium channel 2 (GIRK2). The burst pattern has been shown
to depend on the morphology of the mDA neurons [78] and
requires specific stimulation in vitro [79]. This suggests
that the functional assessment of stem cell-derived mDA
neurons by electrophysiological characterization is met
with several challenges, as the full phenotype depends on
the input of the surrounding network and extracellular
concentration of dopamine [77]. However, as similar action
potential patterns have been identified in iPSC-derived
mDA neurons [73], the electrophysiological profile forms
the third critical characteristic of in vitro differentiated
mDA neurons after protein expression and dopamine
handling.
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Current differentiation strategies for mDA neurons
The strong disease relevance of mDA neurons and their
distinct developmental pathway has driven the differenti-
ation of mDA neurons in vitro. Following the availability
of mouse NPCs, mouse and human ESCs and more
recently iPSCs, different strategies have been developed to
create in vitro cultures rich in mature mDA neurons
(Table 2). The majority of differentiation protocols closely
follow the in vivo developmental stages, progressing from
stem cells to neural rosettes (sometimes via embryoid body
formation) to create neural progenitor cells and begin the
mDA neuron patterning (Fig. 2). Cells at each stage are
supplemented with a cocktail of growth factors reportedly
found during the relevant developmental stages, such as
SHH, FGF8 and BDNF (Table 2). Despite extensive test-
ing of variations in media compositions, including
undefined commercial options, and differentiation timings,
the reported efficiency ratios have remained low with
8–40 % of generated cells expressing TH (Table 2). Higher
yields are promised by the use of SMI, specifically tar-
geting Wnt and GSK3b signaling [80] and factors involved
in floor plate development [81]. However, since GSK3b
signaling is tightly regulated during neurodevelopment
[82], the risk of unintended consequences on mature mDA
neurons remains to be assessed. To ensure the formation of
physiologically relevant cells, the majority of protocols
already go beyond TH expression analysis to identify
mature mDA neurons. Critically, the thoroughness of each
protocol in identifying the derived cultures still varies
widely (Table 2), with two protocols presenting TH
expressing cells without stating their proportion within the
differentiated cultures [80, 83]. By not reporting electro-
physiological characteristics, for example, it remains
unclear whether the created dopamine-producing cells are
close representations of SNc, VTA or other dopamine
neurons. The protocol by Kriks et al. [81] uses fully
adherent differentiation to form a promising foundation for
further development and optimization of mDA neuron
differentiation, with the strong need for identifying the full
spectrum of the generated cultures.
An important shortcoming across all mDA neuron dif-
ferentiation protocols still remains: the direct comparison
of in vitro differentiated neurons with engrafted and in vivo
differentiated neurons. Two of the discussed protocols
engrafted differentiated NPCs [84] or mDA neurons [81]
into rodents, showing that these cells integrate and mature
in their host environment. Neither of the protocols, how-
ever, compared the matured in vitro cultured cells with
their in vivo relatives. The extent to which stem cell
derived mDA neurons differ to their in vivo counterparts
thus remains unclear. This information is vital to assess
whether stem cell derived mDA neurons are appropriate for
the range of questions they have been promised to answer.
Cortical astrocytes
Once defined as the ‘‘nerve glue’’ (neuroglia) for neurons,
astrocytes have emerged as one of the key players in
maintaining cellular homeostasis in the brain and spinal
cord. Astrocytes regulate the ion concentration and remove
excess neurotransmitter and cellular debris from the
extracellular fluid surrounding neurons. In neurodegenera-
tive diseases, however, this vast support network for
neurons is often altered or dysregulated [88]. The dysreg-
ulation of astrocytes can lead to excessive
neuroinflammation, a common pathology in neurodegen-
erative diseases, and contributes to neuronal deterioration
[89]. It is, therefore, important to study the contribution of
astrocytes to neuronal degeneration and disease.
Mammalian development of astrocytes
Astrocyte generation and maturation in vivo relies on
precise temporal and positional stimuli provided by the
cellular environment and neighboring cells [90]. In mice,
the differentiation of astrocytes and other neural cells
begins at E8.5 with neurulation of the neuroectoderm [91].
Neuroepithelial cells from the neuroectoderm firstly dif-
ferentiate into radial glia, the precursors of astrocytes and
NPCs [92]. Although radial glia and astrocytes are over-
lapping in their marker expression of proteins, such as
vimentin and glial fibrillary acidic protein (GFAP) [93], the
morphology, function and time of development differ sig-
nificantly. In the mammalian brain, the main
morphological characteristic of radial glia is their long
processes, which extend from the ventricular zone all the
way to the marginal zone of the pial surface [94]. Through
asymmetric horizontal division, radial glia give rise to
NPCs and initiate neurogenesis. The newly formed NPCs
then migrate along the long processes of radial glia to form
the different layers of the cortex [95]. In the late prenatal
stage and early postnatal stage (E18-P7) in mice, after
neurogenesis and neuronal migration are completed, radial
glia differentiate into astrocytes, a process called
astrogliogenesis.
The differentiation of radial glia and NPCs into astro-
cytes is dependent on the activation of several signaling
pathways. Two of these pathways are the JAK/STAT and
the BMP-SMAD pathway [96]. These pathways are
extrinsically activated by growth factors, including CNTF,
cardiotrophin 1 (CT-1) and leukemia inhibitory factor
(LIF), which are released by early neurons and late NPCs
in vivo. Activation of these mechanisms leads to
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downstream events including chromatin modification and
induction of astrocyte specific gene expression [97].
Transcription factors, such as signal transducer and acti-
vator of transcription 3 (STAT3), mothers against
decapentaplegic homolog 1 (SMAD1), SMAD4 and
nuclear factor 1A (NF1A) are activated and initiate the
expression of GFAP, S100 calcium binding protein B (S-
100b) and glutamate aspartate transporter (GLAST), all of
which are currently used as astrocyte specific markers [98–
100]. Within the first week after birth, astrocytes develop
branched processes and attain their star like structure in the
postnatal brain and spinal cord in mice [101]. Moreover,
expression of the mature astrocyte marker glutamate
transporter 1 (GLT1), a membrane protein important for
the protection of neurons from glutamate-mediated exci-
totoxicity, was observed 2–3 weeks after birth [102].
Mouse studies have further shown that developmental
GLT1 expression is upregulated in vitro when astrocytes
are co-cultured with neurons [103]. This indicates that
neuronal signaling is important for astrocyte maturation.
To successfully differentiate stem cells into functionally
and physiologically relevant astrocytes, the molecular
pathways involved in the cell fate determination of astro-
cytes in vivo need to be replicated in vitro. However, as
most of the developmental studies are based on mouse
models, the translation of this information to human stem
cell differentiation requires careful consideration.
Characteristics of mature astrocytes
In the pursuit of generating functional astrocytes, it is
essential to assess the differentiated cells for the presence
of astrocyte-specific characteristics that are generally
observed in vivo. Morphologically, early astrocytes have
large cell bodies with few processes. However, as astro-
cytes mature, more processes develop, elongate and branch
out, giving the typical ‘star’ shape. In mice, this branching
and elongation of processes takes place during the late
postnatal stages (P14–P27) [104], suggesting that the
astrocyte networks are formed after the maturation of
neighboring neurons.
On the molecular level, the expression of a selection of
proteins is commonly used to characterize cells, in com-
bination with cellular morphology. The most widely used
marker in the characterisation of astrocytes is GFAP.
In vivo mouse studies have shown that GFAP expression
during astrocyte maturation peaks between E16-P1, slowly
decreasing after this time point [105]. Mature astrocytes
only express low levels of GFAP; however, GFAP
expression in mature astrocytes may be upregulated fol-
lowing inflammatory activation [106]. Hence rather than
being a marker for mature and functional astrocytes, GFAP
expression is more indicative of either early immature
astrocytes or reactive astrocytes. Another early develop-
mental astrocyte marker is NF1A, an astrocyte specific
transcription factor. This protein is highly expressed during
mouse embryonic development (E10–E12.5), but its
expression decreases as astrocytes mature [100]. Con-
versely to GFAP and NF1A, the expression of the astrocyte
specific proteins aldolase C (ALDOC), GLAST and GLT1
increase as astrocytes mature [102, 107, 108]. These pro-
teins therefore provide more appropriate markers of mature
astrocytes than the commonly used GFAP. In humans,
expression of the GLAST and GLT1 homologues, excita-
tory amino acid transporter 1 (EAAT1) and EAAT2,
respectively, also increases with gestation time, based on
studies of post mortem fetal brain tissue [109]. As such,
increases in EAAT1 and EAAT2, coupled with a decrease
Fig. 2 Schematic diagram of midbrain dopaminergic neuron differ-
entiation. The differentiation of midbrain dopaminergic neurons from
pluripotent stem cell colonies is driven by the transition from
spherical to adherent cultures and a staggered supplementation of
growth factors, particularly SHH, FGF8 and later TGF3b. The
presence or absence of developmental and maturation markers are
essential guides to monitor the differentiation progress at each
culturing stage towards mature, functional midbrain dopaminergic
neurons
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in the early astrocyte markers, GFAP and NF1A, could be
used as a robust indication of astrocyte maturation.
Other astrocyte specific protein markers commonly
chosen are S100b, aldehyde dehydrogenase 1 family
member L1 (ALDH1L1) and the surface marker protein,
CD44. The expression of these proteins increases at
approximately E13 in mice and the expression profile does
not significantly change throughout development [110–
113]. Thus, while being astrocyte specific markers, these
proteins are unsuitable indicators of astrocyte maturity.
Although the expression profile of astrocyte-specific
proteins provides important information regarding their
maturity, it does not offer information about their func-
tionality. Astrocytes provide a support network for neurons
by closely monitoring and responding to the extracellular
environment. One of the main functions of astrocytes is
protecting neurons from excess neurotransmitter stimula-
tion, by taking up glutamate via GLT1 and GLAST [114].
Additionally, astrocytes are a key player of the innate
immune system of the CNS. As such, they express toll-like
receptors (TLRs), which are able to recognize foreign
particles [115]. Activation of TLRs leads to the release of
chemical signaling molecules, such as cytokines and
chemokines [e.g., interleukin-6 (IL-6), interferon-b and
fractalkine (CX3CL1)] [116]. These molecules recruit and
activate other immune cells to the site of injury. Further-
more, activated astrocytes also release neurotrophic
factors, such as NGF, CNTF and BDNF to aid neuronal
survival and regeneration. The controlled release of these
immune and neurotrophic factors is thus a critical aspect of
astrocyte function, which needs to be confirmed during
in vitro differentiation.
Overall, a panel of marker proteins should be used to
identify the presence of mature astrocytes. Verifying their
functional profile, particularly immune response and neu-
rotransmitter handling, will ensure the relevance of in vitro
astrocytes for modeling disease-relevant processes.
Current differentiation strategies for astrocytes
The generation of mature astrocytes for the purpose of
studying neurological diseases has led to the development
of several astrocyte differentiation protocols from
pluripotent stem cells. However, these protocols vary in
their duration, growth factor conditions and efficiency
(Table 3).
The generation of neural rosettes and NPCs via
embryoid body formation is similar across all protocols,
lasting approximately 21 days. However major variations
between protocols arise during the differentiation and
maturation of NPCs to functional astrocytes. Once NPCs
are present, the most common treatment in the generation
of astrocytes is supplementation with epidermal growth
factor (EGF) and FGF2 (Fig. 3), leading to the generation
of early astrocytes, which has been confirmed by the
expression of CD44, NF1A and vimentin [117–121]. Once
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the presence of early astrocytes is confirmed, the matura-
tion of these cells is generally triggered by the addition of
CNTF (Fig. 3). Although the growth factor conditions are
very similar for most of the protocols (Table 3), a major
difference lies in the maturation duration between each
method. While Krencik et al. [117] matured the differen-
tiated astrocytes for 100 days, the maturation time
described by Emdad et al. [118], Serio et al. [119], Shal-
touki et al. [120] and Mormone et al. [121] vary between
14 and 21 days. The discrepancy in maturation time was
reflected in the proportion of GFAP-expressing cells,
which varied between 55 % [121] and 90 % [117, 119]. To
validate the functionality of the generated cells, some of
these studies also confirmed the ability of astrocytes to take
up glutamate from the cell medium [117, 119, 120].
Unlike the previously described astrocyte differentiation
protocols, Roybon et al. [122] used a different approach in
differentiating astrocytes. The generated NPCs were not
directly differentiated into astrocytes; instead the cells were
first caudalized using RA and ascorbic acid (AA), prior to
treatment with neurotrophic factors, including CNTF, to
generate neurons. The differentiation of astrocytes was
induced by the withdrawal of neurotrophic factors and the
introduction of foetal bovine serum. The generated astro-
cytes were matured for 50–90 days. While previous
protocols assessed the maturation of cells with the
expression of GFAP, Roybon et al. [122] used this protein
as a marker for early astrocytes and EAAT1, EAAT2 and
ALDH1L1 to identify mature astrocytes. Moreover, the
differentiated astrocytes took up glutamate and released IL-
6 upon stimulation with tumor necrosis factor-a and IL-1b
[122]. This study provides initial evidence that the differ-
entiated cells are able to mount an immune response;
however, the complexity of this activation requires further
characterisation.
Further evaluations of astrocyte maturation and function
were conducted by transplanting pluripotent stem cell
derived astrocytes into mice brains [117, 120–122]. These
in vivo experiments primarily demonstrated that trans-
planted cells retained their astrocyte identity as indicated
by the expression of GFAP. Krencik et al. demonstrated
that transplanted differentiated astrocytes were able to form
direct contact with cerebral blood vessels after 6 months,
suggesting that in vitro derived cells are able to mature
in vivo towards functional astrocytes [117]. Conversely,
however, Roybon et al. analyzed marker expression of
engrafted astrocytes in vivo and found high expression of
immature markers, such as NF1A [122]. Thus, even in vivo
transplantation of in vitro generated astrocytes may not be
able to promote full maturation of these cells. Further
characterisation of in vitro differentiated astrocytes is
therefore essential.
In summary, current astrocyte differentiation protocols
use growth factors aligned with reported in vivo develop-
ment. The heavy reliance on GFAP as an indicator for
differentiation success and the limited reporting of func-
tional characteristics prevent a reliable assessment of the
maturity of the created cells. Furthermore, the differentia-
tion periods vary vastly between the protocols, highlighting
the uncertainty about the required phenotype of the gen-
erated astrocytes for relevant experimentation. To date, the
protocol described by Krencik et al. [117] (and Serio et al.
[119]) has reported the highest proportion of GFAP? cells
(90 %) with the confirmation of physiological functions,
such as the propagation of Ca2? waves and glutamate
handling, following a labor-intensive maturation duration
of 4–6 months. Roybon et al. reduced the maturation time
of pluripotent stem cell derived astrocytes to 90 days,
while retaining a similar efficiency [122]. This protocol
[122] relies on several markers to track the maturity of the
Fig. 3 Schematic diagram of astrocyte differentiation. The differen-
tiation of astrocytes from pluripotent stem cell colonies follows the
early neuronal developmental progress through spherical and adherent
culture stages. Glial progenitor formation is triggered by the
supplementation of EGF and FGF2, with CNTF being required for
transition to mature astrocytes and aided by the neurotrophic factor
NRG1b. The presence or absence of developmental and maturation
markers are essential guides to monitor the differentiation progress at
each culturing stage towards mature, functional astrocytes
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generated astrocytes and reports the most extensive phys-
iological confirmation by showing the propagation of Ca2?,
glutamate handling and inflammatory response upon acti-
vation. For the purpose of accurate disease modeling, the
protocol by Roybon et al. shows the essential maturity
confirmation necessary, consisting of a thorough expres-
sion analysis of maturity markers (EAAT1, EAAT2 and
ALDOC), in conjunction with functional characterisation
(neurotransmitter processing and inflammation response)
relevant to the studied disease.
Assessing differentiation techniques
Checklist for high quality and reproducible
differentiated cultures in vitro
Induced pluripotent stem cells offer much promise in
developing in vitro models to understand neurodegenera-
tive disease mechanisms and for testing potential
therapeutics. However, it is essential to generate a mean-
ingful cell population that is both physiologically and
clinically relevant. Evidently, an understanding of the
desired cell type and its key characteristics is necessary to
deliver high quality and reproducible cultures.
The following are common experimental considerations
to promote cell culture purity and consistency when per-
forming or assessing differentiation:
1. Adjust culture environment for each differentiation
stage. The extracellular matrix (ECM) directly and
indirectly affects the maintenance and differentiation
of stem cell and neural cultures [123]. Human ESCs
and iPSCs have been historically cultured on living
feeder cells for mechanical and chemical stimulation,
but recent research has shown that complex ECM
protein combinations are superior in promoting culture
stability and proliferation [124, 125]. The ECM
dynamically evolves during neurodevelopment to form
separate compartments in the CNS [126], comprised of
different ECM protein combinations [127, 128].
Recapitulating in vivo neurodevelopment in culture
thus requires adjustment of the ECM environment for
the desired cell type and developmental stage. Differ-
entiation of neocortical cells has shown to benefit from
combining ECM proteins such as collagen I and
fibronectin [129], but new differentiation protocols
might require performing an ECM microarray [130].
Advanced three-dimensional culture surface modifica-
tion can additionally be used to further the maturation
of the desired cell type [87].
2. Optimize cell counts and the maturation duration of
the protocol. Cell plating density affects
differentiation, potentially due to alterations in effec-
tive local growth factor concentrations. Careful
assessment of the appropriate cell density for plating
needs to be optimized since different cell lines and
different cell types proliferate at different rates. Longer
protocols may be required for mature phenotypes but
can lead to greater differences in the development of
the required cell type compared to contaminating
(unwanted) cell types. For example, developing neu-
rons exit the cell cycle, whereas contaminating cells
may continue to divide unless removed or their growth
is inhibited.
3. Identify checkpoints along the differentiation pathway
and use a panel of cell markers. Expression of
appropriate markers at checkpoints should be con-
firmed; also consider the use of positive or negative
selection of cells, based on cell surface marker
expression. At the final stage of differentiation the
expression of a robust panel of cell-specific markers
should be assessed for each line.
4. Develop reporters to assess differentiated cell types.
Reporters using fluorescent protein expression driven
by an appropriate promoter can be used to identify cell
types of interest. For example, motor neurons differ-
entiated from ESCs have been identified in mixed
cultures via lentiviral delivery of a construct bearing a
GFP driven by the homeobox-9 promoter [131] and
stable GFAP-driven TagRFP has been used to select
iPSC-derived astrocytes [132]. Similar methods can be
employed for other cell types using the promoter
sequence of an appropriate cell-specific marker.
Automated imaging options, such as the Incucyte live
cell imaging system, can be used to provide images
that are free from operator bias. Furthermore, fluores-
cent protein expression can also be used to sort the
cells following differentiation, increasing the purity of
the cell type of interest.
5. Monitor the quality of cultures by assessing cellular
functionality. The expression of a panel of marker
proteins provides some evidence that the appropriate
cell type has been generated. However, there are very
few proteins that are expressed in one cell type alone;
many commonly used (and supposedly cell-specific)
markers are often expressed in multiple cell types.
Further tests are therefore required to confirm that
functional cells have been generated. Functionality can
be assessed using in vitro live cell assays and should
focus on non-biased assessments, such as receptor
ligand quantification in culture medium, prior to
experimental use.
The steps involved in developing and optimizing a dif-
ferentiation protocol are outlined in Box 1.
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Increasing the quality of cultures—suggestions
for improvement
Cell culture experiments need to mimic the physiological
environment as closely as possible, in order to yield bio-
logically relevant conclusions. The following
developments will allow the experimental set-up to more
closely represent the in vivo cellular background:
1. Use of a hypoxic chamber to prevent chronic oxidative
stress. The majority of cell culture experiments are
performed under atmospheric oxygen conditions, i.e.
21 % O2. However cells in the brain and much of the
body experience far lower levels, thought to range
between 1 and 11 % O2 [133]. Recent data suggests
that the process of reprogramming somatic cells to
iPSCs is more efficient when performed under hypoxic
conditions [134, 135]. Reprogramming requires a shift
in cellular metabolism from oxidative to glycolytic
conditions [10] and the hypoxia-inducible factors play
a role in the coordination of these metabolic changes
[136]. Comparisons of differentiation protocols under
atmospheric vs. physiological O2 conditions are still
limited. However, in the case of differentiation of
cardiomyocytes, hypoxic culture increased differenti-
ation yields by up to 1000-fold [137]. Measurements
throughout the brain suggest that local oxygen tensions
are heterogeneous in nature, exhibiting spatial and
temporal differences depending on the microenviron-
ment [138]. For example, neurons of the cerebral
cortex experience a low oxygen field compared to
venous O2 [138]. Neurons in such an oxygen environ-
ment are more sensitive to changes in cerebral blood
flow, in the provision of oxygen and nutrients and are
potentially more sensitive to oxidative stress. Investi-
gations using in vivo imaging, for example by two-
photon microscopy, allow the mapping of the partial
pressure of oxygen at the lm/s resolution [139]. A
detailed understanding of the local oxygen environ-
ment will allow us to provide in vivo conditions during
in vitro experiments, an important consideration for
further development. Future studies need to consider
the implications of performing differentiation, and
experiments, at atmospheric O2.
2. Problems with feeding cycles could be partially
overcome with microfluidics or bioreactors. A consid-
eration in cell differentiation is the consistent and
appropriate provision of nutrients and growth factors.
Traditional cell feeding cycles of every 24 or 48 h can
lead to dramatic variations in nutrient delivery and
gradients of trophic factors. During the course of a
culture, the concentrations of glucose, growth factors
and micronutrients can vary widely in the growth
medium, along with the pH. The proliferation and
differentiation of stem cells is drastically affected by
growth medium supplements [140], with the outcome
that under different nutrient conditions the same cell
line could yield different phenotypes. Microfluidics
can be used to manipulate the delivery of medium on
the micrometer scale, allowing for more controlled
temporal and spatial supply of nutrients [141]. Alter-
natively larger cell preparations could be cultured in
bioreactors that stir the growth medium; agitation has
led to higher yields of differentiated cells in some
protocols [137]. The use of bioreactors that are
engineered to cultivate three-dimensional cultures,
under hypoxic conditions, provides a further promising
development [142].
3. Development of accurate co-culture systems and three-
dimensional cultures. The architecture of the brain is
clearly a complex multicellular environment. The
presence of diverse cell types in cultures can be
detrimental when studying cell-specific effects. How-
ever, a mixture of cell types may be required to
understand a particular cellular process, such as
Box 1: Checklist for diﬀerenang meaningful neural cell cultures from pluripotent stem cells
A. Select appropriate diﬀerenaon protocol
1. Method creates suitable cell type composion for hypothesis tesng
2. Cell phenotype characteriscs can be developed in vitro
3. Diﬀerenaon process follows in vivo developmental pathway
B. Opmize culturing method
1. Adjust cell seeding density and media supplement concentraons to each stem cell line
2. Adjust O2 concentraon for opmal diﬀerenaon and hypothesis tesng
3. Modify extracellular environment for each diﬀerenaon stage
C. Conﬁrm culture quality
1. Monitor diﬀerenaon progress via marker expression consistency at relevant check points
2. Record culture composion via expression raos of relevant markers for each line
3. Perform funconal assays to conﬁrm culture suitability for hypothesis tesng
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neuronal:glial interactions or neuroinflammation. In
addition, other cell types may be required for appro-
priate maturation. For example, astrocytes are required
for the maturation of functional synapses [143] and in
organizing the neuronal extracellular matrix [144]. As
differentiation protocols improve so does our capacity
for generating the appropriate mix of cells that
function together. A key aspect of many neurodegen-
erative disorders is that multiple cell types are affected.
Being able to accurately model the system holistically
would be a huge leap forward in understanding the role
of cellular interactions in disease pathogenesis. The
generation of specific neuronal and glial subtypes
remains under-developed. To accurately model the
brain for neurodegenerative disease research, future
studies will need to address the issue of subtype
specification, potentially incorporating single cell
analysis. In the case of excitable cells, cell function
can be analyzed by electrophysiological assessment,
coupled with single cell reverse transcription PCR to
characterize the molecular signature of the cells
generated. Faithful recapitulation of the molecular
profile of specific cell subtypes is an important goal for
future research.
Conclusions
Creating in vitro models of central nervous system disor-
ders with human stem cells provides the medical research
community with a powerful new research tool. To ensure
the use of this option to its full potential, differentiation
strategies need to be carefully planned and executed
depending on the cell type desired and the experimental
read-out. Confirmation of a robust panel of cell-specific
markers, coupled with functional assays, is further required
to provide evidence that the appropriate developmental
pathway has been effectively recapitulated. Future studies
need to focus on cultivating cells in more physiologically
relevant environments by manipulating oxygen tension,
overcoming issues with growth factor and nutrient gradi-
ents and developing multicellular and three-dimensional
culture systems. Employing these quality improvement and
control measures will lead to more reliable and repro-
ducible results with strong clinical relevance.
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